Version history

{
  "session_id": "sess_SDA-2026-04-01-gap-lipid-rafts-2026-04-01",
  "round_number": 5,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514-v1:0",
  "action": "synthesize",
  "content": "```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"Nicotinic Receptor-Lipid Raft Co-Modulators\",\n      \"description\": \"Co-targeting CHRNA7 and LDLR to restore spatial cross-talk between cholinergic signaling and membrane domains disrupted in AD\",\n      \"target_genes\": [\"CHRNA7\", \"LDLR\"],\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.85,\n        \"evidence_strength\": 0.80,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.85,\n        \"therapeutic_potential\": 0.80,\n        \"druggability\": 0.90,\n        \"safety_profile\": 0.70,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.85,\n        \"reproducibility\": 0.75\n      },\n      \"composite_score\": 0.785,\n      \"supporting_evidence\": \"EVP-6124 Phase 2 completed (NCT01073228), established α7 nAChR regulatory pathway, strong mechanistic rationale from PMID:31379503\"\n    },\n    {\n      \"title\": \"Cholesterol-Sphingolipid Ratio Modulators as Synaptic Rescuers\",\n      \"description\": \"Therapeutic restoration of optimal cholesterol:sphingolipid ratios in synaptic lipid rafts to reverse amyloid-β induced membrane domain disruption\",\n      \"target_genes\": [\"HMGCR\", \"SPHK1\"],\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.75,\n        \"evidence_strength\": 0.70,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.50,\n        \"therapeutic_potential\": 0.75,\n        \"druggability\": 0.60,\n        \"safety_profile\": 0.60,\n        \"competitive_landscape\": 0.40,\n        \"data_availability\": 0.70,\n        \"reproducibility\": 0.65\n      },\n      \"composite_score\": 0.645,\n      \"supporting_evidence\": \"Statin precedent but multiple AD trial failures, no validated SPHK1 inhibitors, requires novel biomarker development\"\n    },\n    {\n      \"title\": \"APP Processing Compartmentalization Therapeutics\",\n      \"description\": \"Selective targeting of secretase localization to shift APP processing from amyloidogenic to non-amyloidogenic pathways\",\n      \"target_genes\": [\"PSEN1\", \"ADAM10\"],\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.80,\n        \"evidence_strength\": 0.75,\n        \"novelty\": 0.85,\n        \"feasibility\": 0.25,\n        \"therapeutic_potential\": 0.90,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.20,\n        \"competitive_landscape\": 0.20,\n        \"data_availability\": 0.60,\n        \"reproducibility\": 0.50\n      },\n      \"composite_score\": 0.535,\n      \"supporting_evidence\": \"Strong mechanistic basis but catastrophic precedents (Semagacestat failure), Notch toxicity concerns, regulatory death valley\"\n    },\n    {\n      \"title\": \"Synaptic Raft Rejuvenation via Ceramide Metabolism\",\n      \"description\": \"Targeting ceramide production and sphingomyelin hydrolysis to restore youthful raft composition\",\n      \"target_genes\": [\"SMPD1\", \"CERS2\"],\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.70,\n        \"evidence_strength\": 0.60,\n        \"novelty\": 0.90,\n        \"feasibility\": 0.20,\n        \"therapeutic_potential\": 0.70,\n        \"druggability\": 0.25,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.80,\n        \"data_availability\": 0.40,\n        \"reproducibility\": 0.45\n      },\n      \"composite_score\": 0.550,\n      \"supporting_evidence\": \"Novel approach but SMPD1 undruggable, no clinical compounds available, limited feasibility\"\n    },\n    {\n      \"title\": \"Cholinergic-Lipid Raft Interface Modulators\",\n      \"description\": \"Simultaneous enhancement of acetylcholine synthesis and cholesterol efflux from synaptic membranes\",\n      \"target_genes\": [\"CHAT\", \"ABCA1\"],\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.65,\n        \"evidence_strength\": 0.60,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.30,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.35,\n        \"safety_profile\": 0.70,\n        \"competitive_landscape\": 0.50,\n        \"data_availability\": 0.50,\n        \"reproducibility\": 0.50\n      },\n      \"composite_score\": 0.545,\n      \"supporting_evidence\": \"Limited druggability of CHAT, no viable small molecule ABCA1 modulators\"\n    },\n    {\n      \"title\": \"Membrane Fluidity Gradient Therapeutics\",\n      \"description\": \"Creating controlled membrane fluidity gradients through cholesterol esterification and sphingomyelin synthesis modulation\",\n      \"target_genes\": [\"SOAT1\", \"SGMS1\"],\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.60,\n        \"evidence_strength\": 0.50,\n        \"novelty\": 0.95,\n        \"feasibility\": 0.15,\n        \"therapeutic_potential\": 0.60,\n        \"druggability\": 0.20,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.90,\n        \"data_availability\": 0.30,\n        \"reproducibility\": 0.35\n      },\n      \"composite_score\": 0.495,\n      \"supporting_evidence\": \"Highly speculative mechanism, no validated compounds, unclear druggability\"\n    },\n    {\n      \"title\": \"Synaptic Membrane Domain Stabilizers\",\n      \"description\": \"Targeting membrane domain organizing proteins to stabilize liquid-ordered domains necessary for synaptic function\",\n      \"target_genes\": [\"FLOT1\", \"CAV1\"],\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.65,\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.10,\n        \"therapeutic_potential\": 0.60,\n        \"druggability\": 0.15,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.85,\n        \"data_availability\": 0.40,\n        \"reproducibility\": 0.40\n      },\n      \"composite_score\": 0.500,\n      \"supporting_evidence\": \"Structural proteins are undruggable targets, no chemical matter available\"\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"CHRNA7\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"lipid_rafts\",\n      \"target_type\": \"cellular_structure\",\n      \"relation\": \"co_localizes_in\"\n    },\n    {\n      \"source_id\": \"lipid_rafts\",\n      \"source_type\": \"cellular_structure\",\n      \"target_id\": \"APP_processing\",\n      \"target_type\": \"biological_process\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"cholesterol\",\n      \"source_type\": \"metabolite\",\n      \"target_id\": \"membrane_fluidity\",\n      \"target_type\": \"biophysical_property\",\n      \"relation\": \"determines\"\n    },\n    {\n      \"source_id\": \"HMGCR\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"cholesterol_synthesis\",\n      \"target_type\": \"metabolic_pathway\",\n      \"relation\": \"catalyzes\"\n    },\n    {\n      \"source_id\": \"PSEN1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"gamma_secretase\",\n      \"target_type\": \"protein_complex\",\n      \"relation\": \"component_of\"\n    },\n    {\n      \"source_id\": \"sphingolipids\",\n      \"source_type\": \"metabolite\",\n      \"target_id\": \"raft_stability\",\n      \"target_type\": \"biophysical_property\",\n      \"relation\": \"maintains\"\n    },\n    {\n      \"source_id\": \"LDLR\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"cholesterol_homeostasis\",\n      \"target_type\": \"biological_process\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"membrane_domains\",\n      \"source_type\": \"cellular_structure\",\n      \"target_id\": \"protein_sorting\",\n      \"target_type\": \"biological_process\",\n      \"relation\": \"mediates\"\n    }\n  ],\n  \"synthesis_summary\": \"The synthesis reveals a clear feasibility hierarchy among the lipid raft therapeutic hypotheses, with the nicotinic receptor-lipid raft co-modulator approach (CHRNA7 + LDLR) emerging as the most viable candidate. This hypothesis achieves the highest composite score (0.785) by combining strong mechanistic plausibility based on spatial cross-talk evidence from PMID:31379503 with excellent druggability through existing α7 nAChR compounds like encenicline and established statin-based LDLR modulation. The regulatory pathway is well-precedented through completed Phase 2 trials (NCT01073228), and the combination approach offers genuine novelty in addressing both neurotransmitter deficits and membrane environment simultaneously. However, critical success depends on developing lipid raft composition biomarkers as companion diagnostics for target engagement.\\n\\nThe analysis exposes a fundamental tension between mechanistic innovation and practical implementation across all hypotheses. While the cholesterol-sphingolipid ratio modulators and APP compartmentalization approaches show strong theoretical foundations, they face substantial barriers including failed statin precedents in AD, lack of validated SPHK1 inhibitors, and the regulatory toxicity surrounding γ-secretase modulation post-Semagacestat failures. The knowledge graph reveals key therapeutic leverage points in the cholesterol-sphingolipid-membrane fluidity axis and the spatial organization of APP processing machinery, but translating these insights requires focusing on the most tractable molecular targets with existing pharmacological tools and established safety profiles.\"\n}\n```",
  "tokens_used": "2216",
  "persona_id": "persona-synthesizer"
}